期刊
JOURNAL OF CLINICAL NEUROSCIENCE
卷 44, 期 -, 页码 84-88出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2017.06.044
关键词
EMP2; Glioblastoma; Antibody therapy; Epithelial membrane protein 2
资金
- AMA Foundation
- AOmegaA Carolyn L. Kuckein Student Research Fellowship
- Gurtin Skull Base Research Fellowship
- NCI [R01 CA163971]
- UCLA
- Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research UCLA Scholars in Translational Medicine Program Award
- Jason Dessel Memorial Seed Grant
- Stop Cancer! Research Career Development Award
Epithelial membrane protein 2 (EMP2) is a cell surface protein that has recently emerged as an object of neuro-oncological interest due to its potential to be utilized as a biomarker and target for antibody therapies. Preclinical studies have demonstrated that EMP2 is associated with disease prognosis in a number of human cancers, including glioblastoma. The four large extracellular domains of EMP2 and its association with the extracellular matrix makes it an attractive target for future cancer therapies. Translational research suggests that EMP2 may be targeted with antibodies to improve tumor control and survival in a variety of murine models and cancer types. However, in order to translate these preclinical findings into the clinic, future research will need to focus on elucidating the role EMP2 in the normal human body by better understanding its molecular and chemical interactions. The focus of this review is to provide a comprehensive insight into current research endeavors, discuss the potential for clinically translatable applications, and predict the future directions of such research. (C) 2017 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据